# Combination of Toripalimab and JS004 Therapy for ccRCC

> **NCT06690697** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 80 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** JS004
- **DRUG:** Toripalimab
- **DRUG:** Axitinib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT06690697
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690697, "Combination of Toripalimab and JS004 Therapy for ccRCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06690697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*